NOT-DA-00-011: CARDIOVASCULAR AND SAFETY EVALUATIONS OF POTENTIAL MEDICATIONS TO REDUCE DRUG USE

Department of Health
and Human Services (HHS)

NIH... Turning Discovery Into Health^®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.

CARDIOVASCULAR AND SAFETY EVALUATIONS OF POTENTIAL MEDICATIONS TO REDUCE DRUG USE Release Date: March 9, 2000 NOTICE: DA-00-011 RFP AVAILABLE: N01DA-0-8805 National Institute on Drug Abuse The National Institute on Drug Abuse is soliciting proposals from qualified organizations having the in-house capacity to perform experiments in laboratory animals to systematically evaluate the cardiovascular and toxicological effects of potential treatment drugs, both new and marketed, for treatment of drug abuse. Specifically, treatment drugs for two classes of drugs of abuse (stimulants and opiates) will be investigated pre-clinically. Due to the nature of the compounds which may be evaluated, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970, and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. Further, all offerors must be in compliance with the NIH guidelines on the care and use of laboratory animals and, the laboratory must be operated according to the FDA’s Good Laboratory Practices Program. It is estimated that a five-year incrementally funded level of effort type contract will result from this procurement. The project will include options for additional effort to cover additional testing. RFP No. N01DA-0-8805 will be available electronically on or about March 27, 2000, and may be accessed through the NIDA website at the following address: (URL: http://www.nida.nih.gov/RFP/RFPList.html) Please note that the RFP for this acquisition will be streamlined to include only the Work Statement, Deliverables and Reporting Requirements, Special Requirements and Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. All information required for the submission of an offer will be contained in or accessible through the electronic RFP package. Response to the RFP will be due on or about May 25, 2000. Any responsible offeror may submit a proposal which will be considered by the Government. This advertisement does not commit the Government to award a contract. Point of Contact: Kenneth E. Goodling, Contracting Officer National Institute on Drug Abuse, NIH Contracts Management Branch, OPRM 6001 Executive Blvd., Room 3105, MSC 9543 Bethesda, Maryland 20892-9543 Electronic Mail Address: kg25d@nih.gov Telephone: (301) 443-6677 Fax: (301) 443-7595

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices